Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.81 -3.46 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
63 64 Next >
Investing Trends to Follow in 2024
We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture?
Via Benzinga
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
With a new medicine on the market and plenty of money, Vertex is in great shape. 
Via The Motley Fool
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
The Best Stocks to Invest $1,000 in Right Now
It's not too late to get in on these market beaters. 
Via The Motley Fool
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
Via Investor Brand Network
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.
These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. 
Via The Motley Fool
Topics Stocks
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.
These stocks offer attractive risk-reward profiles. 
Via The Motley Fool
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
It's been a crazy year across sectors, but winners remain. 
Via The Motley Fool
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
3 Monster Stocks to Buy Without Any Hesitation
These are easy choices for investors seeking market-beating long-term gains. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
Editas isn't out of the woods yet, but it's better off than before. 
Via The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
5 Top Stocks to Buy With Your End-of-the-Year Bonus
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Both develop medicines for rare diseases, and each aims to conquer a niche market. 
Via The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.